Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Follicle stimulating hormone (FSH) or follitropin is a hormone of the gonadotropin type, which is found normally in the body. It is synthesized and secreted by gonadotroph cells from the anterior part of the pituitary gland.
FSH regulates pubertal maturation. In women, it matures the oocytes of the ovary and stimulates the production of estradiol (estrogen hormone). In men it regulates the production of sperm.
UROFOLLITROPIN is a human follitropin derived from purified human menopausal gonadotropin (HMG). Other follitropins are obtained by recombinant engineering (follitropin alpha, beta and delta) with similar uses and effectiveness (Weiss 2019, Taketani 2010, Baker 2009).
It is used in infertility treatments (including polycystic ovary syndrome) to induce ovulation in anovulatory patients who do not respond to clomiphene and for the development of multiple follicles (ovarian hyperstimulation) in ovulatory patients in assisted reproduction programmes.
Subsequently, human chorionic gonadotropin (hCG) is usually administered to trigger ovulation.
Subcutaneous or intramuscular administration of a daily dose with ovarian ultrasound monitoring, for 7 to 14 days according to evolution.
Since the last update we have not found published data on its excretion in breastmilk.
Its high molecular weight makes its excretion in breastmilk very unlikely.
Due to its proteinaceous nature it is inactivated in the gastrointestinal tract, not being absorbed, (oral bioavailability is practically zero), which impedes transfer to infant plasma from breastmilk, except in premature babies and the immediate neonatal period, when there may be more intestinal permeability.
There is no proof that its estrogenic effects decrease milk production.
-------------------------------------------------- --------
BREASTFEEDING and INFERTILITY TREATMENTS
In assisted reproduction treatments (ART) for infertility, two issues must be taken into account:
1. The possible effects of ART on the infant or breastfeeding.
The medication used, in general, does not interfere with breastfeeding and does not affect the infant, who in these cases is usually older than 6 months and even 1 or 2 years old.
2. The possible interference of breastfeeding with ART.
Breastfeeding, especially frequent, could hinder ovulation. This is the main reason why assisted reproduction services recommend suspending breastfeeding before starting treatment which is usually emotionally costly and, often, also from a financial perspective.
To date, there is no published data that proves that breastfeeding is incompatible with assisted reproduction techniques (ART).
See below the information of these related products: